Roivant Sciences
Develops immunology medicines and delivery technologies through focused Vant subsidiaries.
$34.44
After-hours close−0.25 (−0.72%)
At close$34.69(−7.69%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 79.97%577.70M sharesInsiders 10.45%75.50M sharesOther 9.58%69.20M shares
Shares outstanding 722.41M · Float 577.47M · 79.9% free float
Institutions13F, as of Jun 30, 2026
516 holders · 577.70M shares · 98 new positions · 301 increased · 140 reduced · 47 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 81.02M | 11.22% | +3.04M | Aug 13, 2026 |
| BlackRock, Inc. | 48.24M | 6.68% | +3.98M | Aug 7, 2026 |
| Morgan Stanley | 42.59M | 5.90% | −9.24M | Aug 13, 2026 |
| QVT Financial LP | 23.72M | 3.28% | −1.44M | Aug 14, 2026 |
| Vanguard Capital Management LLC | 22.12M | 3.06% | +1.44M | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 21.64M | 3.00% | +1.80M | Aug 13, 2026 |
| Goldman Sachs Group Inc | 18.56M | 2.57% | +7.44M | Aug 14, 2026 |
| State Street Corp | 17.80M | 2.46% | +1.61M | Aug 7, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 10.30% | 73.64M | 13G | Mar 6, 2026 ↗ |
| Morgan Stanley | 6.90% | 49.47M | 13G | May 12, 2026 ↗ |
| BlackRock, Inc. | 5.70% | 41.96M | Nov 8, 2024 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Ramaswamy Vivek | 10 percent owner | 47.01M | 6.51% | Dec 15, 2025 |
| Daniel Allen Gold | director | 22.66M | 3.14% | Jun 30, 2026 |
| Mayukh Sukhatme | director, officer: President & CIO | 18.63M | 2.58% | Aug 21, 2026 |
| Matthew Gline | director, officer: CEO | 16.66M | 2.31% | Jul 2, 2026 |
| Frank Torti | officer: President and Vant Chair | 13.54M | 1.87% | Jul 2, 2026 |
| Keith S. Manchester | director | 1.75M | 0.24% | Jun 30, 2026 |
| Eric Venker | officer: President & Immunovant CEO | 1.60M | 0.22% | Aug 24, 2026 |
| Richard Pulik | officer: CFO | 271.8K | 0.04% | Aug 24, 2026 |
| Ilan Oren | director | 121.0K | 0.02% | Jul 21, 2026 |
| James C. Momtazee | director | 109.8K | 0.02% | Jul 21, 2026 |
5 ten-percent owners hold 192.58M shares by Form 4, outside the officers-and-directors figure above · 6 people have not refiled in the last 18 months (203.13M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 21, 2026 | Mayukh Sukhatmedirector, officer: President & CIO | Sale | 144,756 | $36.48 | 18,630,739 |
| Aug 20, 2026 | Mayukh Sukhatmedirector, officer: President & CIO | Sale | 17,519 | $37.30 | 18,630,739 |
| Aug 19, 2026 | Mayukh Sukhatmedirector, officer: President & CIO | Sale | 172,899 | $37.17 | 18,630,739 |
| Aug 18, 2026 | Mayukh Sukhatmedirector, officer: President & CIO | Sale · 2 lots | 136,942 | $36.73 | 18,630,739 |
| Aug 17, 2026 | Mayukh Sukhatmedirector, officer: President & CIO | Sale | 284,707 | $36.25 | 18,630,739 |
| Aug 14, 2026 | Mayukh Sukhatmedirector, officer: President & CIO | Sale | 243,177 | $36.23 | 18,630,739 |
| Jul 27, 2026 | Eric Venkerofficer: President & Immunovant CEO | Sale | 200,000 | $34.95 | 1,613,063 |
| Jun 30, 2026 | Meghan Fitzgeralddirector | Sale | 10,000 | $34.90 | 42,963 |
| Jun 29, 2026 | Melissa B. Epperlydirector | Sale · 2 lots | 17,750 | $34.38 | 16,474 |
| Jun 30, 2026 | QVT Financial LPother: Director by Deputization | Sale | 12,380 | $35.28 | 13,689,166 |
CongressHouse and Senate disclosures
Not reported.